Mechanical Circulatory Support in Patients with End-Stage Heart Failure

  • V. G. Tanskyi Kovel Regional Territorial Medical Association, Cardiovascular Surgery Center, Kovel, Ukraine
DOI: https://doi.org/10.30702/transpaorg/02_20.0112/018-039/089
Keywords: chronic heart failure, LVAD therapy, BiVAD-therapy, orthotopic heart transplantation

Abstract

Objective. The aim of the study is to establish the effectiveness of mechanical support of blood circulation of patients with end-stage heart failure depending on the method of surgical correction.

Materials and methods. The results of the study are based on the data of examination and dynamic observation of 73 patients (median age 44 (16-69) years, 68 men, 5 women) who were treated from 2008-2019 іn the following medical institutions: Republican Scientific and Practical Center «Cardiology» (Minsk, Republic of Belarus) and Center of cardiac surgery on the basis of Hospital «Feofania». Patients were examined during the initial examination, after 3 months and after 1 year.

Results and discussion. As a result of the study found, indications for surgical treatment of patients with end-stage heart failure those are the following criteria: left ventricular ejection fraction (LV EF) <20%, (p < .0001). Pulmonary artery occlusion pressure (PAL) from 25 mm Hg up to 35 mm Hg (p < .0001). Peak myocardial oxygen consumption <14 ml/kg/min on the background of maximum drug therapy (p < .0001). Pulmonary vascular resistance (PVR) <5 units by Wood, (p < .0001). Transpulmonary gradient up to 15 mm Hg (p < .0001). Indications for LVAD therapy are the following criteria: left ventricular ejection fraction (LV EF) <20%, (p <0001). Pulmonary artery occlusion pressure > 35 mm Hg (p < .0001). Pulmonary vascular resistance (PVR) >5 units by Wood, (p < .0001). Transpulmonary gradient >15 mm Hg (p < .0001). Against the background of work LVAD after 3 months there was a decrease in the left ventricular cavity by 30%, (p < .0001), decrease in the pancreatic cavity by 25.5%, (p < .0001), increase in fraction LV emission by 21%, (p < .0001). According to direct pulmonary arterial tonometry with LVAD therapy, there was a decrease in pulmonary vascular resistance «Wood» by 34%, (p < .0001), reduction in pulmonary arterial pressure by 24%, (p < .0001), a decrease of transpulmonary gradient by 21%, (p < .0001). The results of the change in functional indicators in patients on LVAD therapy after 3 months: increase maximum myocardial oxygen consumption by 6% (p < .0001), increase exercise tolerance by 15% (p < .0001). Indications for BiVAD-therapy are the following criteria: biventricular insufficiency, (p < .0001). Pulmonary artery occlusion pressure >35 mm Hg, (p < .0001). Pulmonary vascular resistance >5 units by Wood, (p < .0001). Transpulmonary gradient >15 mm Hg, (p < .0001). Against the background of BiVAD work in 3 months was noted reduction of the right ventricular (RV) enddiastolic volume (EDV) by 6% (p <0001), reduction of the RV end-systolic volume (ESV) by 10%, (p < .0001), increase in LV EF by 33%, (p < .0001), decrease in left ventricular (LV) ESV (M-mode) by 36.3%, (p < .0001), a decrease in LV EDV (M-mode) by 30%, (p < .0001), a decrease in LV ESV (B-mode) by 22.5%, (p < .0001), increase in tricuspid systolic excursion (TAPSE) by 21.4%, (p < .0001). According to the direct pulmonary arterial tonometry during use BiVAD-therapy: reduction of pulmonary vascular resistance «Wood» by 22%, (p < .0001), reduction of pulmonary arterial pressure by 15%, (p <0001), reduction of transpulmonary gradient by 14%, (p <0001). The results of surgical treatment of patients with critical heart failure: after direct orthotopic heart transplantation (OHT): 24 patients were treated with positive result (92%), 2 patients died (8%). There were 18 patients performed secondary OHT, patients who were on LVAD therapy (46%). 18 patients (46%) continue LVAD-therapy. On LVAD-therapy 3 patients died (8%). The cause of death is purulent-septic lesions. Which patients were on BiVAD-therapy: secondary OHT performed 4 patients (50%). 4 patients (50%) died on BIVAD-therapy. The cause of death in 2 cases was purulent-septic lesions (50%), and in 2 other cases it was multisystem organ failure (50%)

Conclusions. Analysis of the results of the differential approach to surgical treatment patients with heart failure NYHA functional class III-IV: patients with critical heart failure in the presence of contraindications to direct heart transplantation, it is advisable to consider the use of long-term mechanical circulatory support based on LVAD therapy (p < .0001) and BiVAD-therapy (p < .0001) as a mechanical bridge to heart transplantation. Applied long-term mechanical support of blood circulation in patients with high indicators of pulmonary hypertension (p < .0001), allows in a short time (4-6 weeks) to normalize pulmonary artery pressure and consider performing a secondary heart transplant.

References

  1. Katz JN, Waters SB, Hollis IB, Chang PP. Advanced therapies for end-stage heart failure. Curr Cardiol Rev. 2015;11:63-72.
  2. Kittleson MM. Changing Role of Heart Transplantation. Heart Fail Clin. 2016;12:411-421.
  3. Prinzing A, Herold U, Berkefeld A, Krane M, Lange R, Voss B. Left ventricular assist devices-current state and perspectives. J. Thorac. Dis. 2016; 8: E660-E666.
  4. Aeronson KD, Patel H, Pagani FD. Patient selection for left ventricular assist device therapy. Ann. Thorac. Surg. 2003;75(6 supll):S29-S35.
  5. Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, et al. Sixth INTERMACs annual report: a 10,000-patient database. J. Heart Lung Transpl. 2014; 33: 555-564.
  6. Deschkа H, Holthaus AJ, Sindermann JR, Welp H, Schlarb D, Monsefi N, et al. Can Perioperative Right Ventricular Support Prevent Postoperative Right Heart Failure in Patients With Biventricular Dysfunction Undergoing Left Ventricular Assist Device Implantation? J Cardiothorac. Vasc. Anesth. 2016;30:619-626.
  7. Eckman P, Liao K. Right ventricular failure – a continuing problem in patients with left ventricular assist device support. J. Cardivasc. Transpl. Res. 2010;3:604-611.
  8. Cushing K, Kushnir V. Gastrointestinal Bleeding Following LVAD Placement from Top to Bottom. Dig. Dis. Sci. 2016 Jun;61(6):1440-1447.
  9. Robertson J, Long B, Koyfman A. The emergency management of ventricular assist devices. Am. J. Emerg. Med. 2016; 34 (7): 1294-1301.
  10. Castel MA, Cartana R, Cardona D, Hernandez M, Sandoval E, Castella M, Perez-Villa F. Long-term outcome of high-urgency heart transplant patients with and without temporary ventricular assist device support. Transplant. Proc. 2012;44(9):2642-2644.
  11. Barth E, Durand M, Heylbroeck C, Rossi-Blancher M, Boignard A, Vanzetto G, et al. Extracorporeal life support as a bridge to high-urgency heart transplantation. Clin. Transplant. 2012;26(3):484-488.
  12. D’Alessandro C, Coldmar Jl, Lebreton G, Laali M, Varnous S, Farahmand P, et al. High-urgency waiting list for cardiac recipients in France: single-centre 8-year experience. Eur. J. Cardiothorac. Surg. 2017 Feb 1;51(2):271-278. https://doi.org/10.1093/ejcts/ezw291
  13. Kittleson MM, Patel JK, Moriguchi JD, Kawano M, Davis S, Hage A, et al. Heart transplant recipients supported with extracorporeal membrane oxygenation: outcomes from a single-center experience. J. Heart Lung Transplant. 2011; 30 (11): 1250-1256.
  14. Hullin R. Heart transplantation: current practice and outlook to the future. Swiss Med. Wkly. 2014;144:w13977.
  15. Davis MK, Hunt SA. State of the art: cardiac transplantation. Trends Cardiovasc. Med. 2014;24 (8): 341-349.
  16. Silva EJ. Mechanical Circulatory Support: Current Status and Future Directions. Prog. Cardiovasc. Dis. 2016;58(4):444-454.
  17. Lund LH, Edward LD, Kucheryavaya AY, Benden C, Dipchand AI, Goldfarb S, et al. The registry of the international society for heart and lung transplantation: thirty-second official adult heart transplantation Report--2015; focus theme: early graft failure. J. Heart Lung Transplant. 2015;34:1244-1254.
  18. Subramaniam K. Mechanical circulatory support. Best Pract. Res. Clin. Anaesthesiol. 2015;29: 203-227.
  19. Sajgalik P, Grupper A, Edwards BS, Kushwaha SS, Stulak JM, Joyce DL, et al. Current Status of Left Ventricular Assist Device Therapy. Mayo Clin. Proc. 2016;91:927-940.
  20. Dang NC, Topkara VK, Mercando M, Kay J, Kruger KH, Aboodi MS, et al. Right heart failure after left ventricular assist device implantation in patients with chronic congestive heart failure. J. Heart Lung Transplant. 2006;25:1-6.
  21. Meineri M, Van Rensburg AE, Vegas A. Right ventri cular failure after LVAD implantation: prevention and treatment. Best Pract. Res. Clin. Anaesthesiol. 2012; 26:217-229
  22. Estep AD, Cordero-Reyes AM, Bhimarai, Trachtenberg B, Khalil N, Loebe M, A et al. Percutaneous Placement of an Intra-Aortic Balloon Pump in the Left Axillary/Subclavian Position Provides Safe, Ambulatory Long-Term Support as Bridge to Heart Transplantation. JACC Heart Failure. 2013;1:382-8.
  23. Cochran RP, Starkey TD, Panos AL, Kunzelman KS. Ambulatory intraaortic balloon pump use as bridge to heart transplant. Ann. Thorac. Surg 2002 Sep; 74 (3): 746-751.
  24. Umakanthan R, Hoff SJ, Solenkova N, Wigger MA, Keebler ME, Lenneman A, et al. Benefits of ambulatory axillary intra-aortic balloon pump for circulatory support as bridge to heart transplant. J. Thorac. Cardiovasc. Surg. 2012May;143(5):1193-1197.
  25. Briceno N, Kapur NK, Perera D. Percutaneous mechanical circulatory support current concepts and future directions. Heart. 2016; 102: 1494-1507.
  26. Fuhrman BP, Hernan LJ, Rotta AT, Heard CM, Rosenkranz ER. Pathophysiology of cardiac extracorporeal membrane oxygenation. Artif Organs. 199923(11):966-9.
Published
2020-12-16
How to Cite
Tanskyi , V. G. (2020). Mechanical Circulatory Support in Patients with End-Stage Heart Failure. Transplantation and Artificial Organs, (1(01), 19-40. https://doi.org/10.30702/transpaorg/02_20.0112/018-039/089
Issue
Transplantation and artificial organs №1(01) 2020
Section
SCIENTIFIC PUBLICATIONS